Pioglitazone hydrochloride/glimepiride
Pioglitazone hydrochloride/glimepiride
复制标题
DOI：
10.1358/dot.2007.43.7.1073850
复制
发表时间：
2007-07-01
期刊：
影响因子：
1.8
通讯作者：
Blake, Elizabeth W.
中科院分区：
文献类型：
--
作者：
Blake, Elizabeth W.
盐酸吡格列酮（一种噻唑烷二酮）和格列美脲（一种磺酰脲）的组合已在全球许多国家被批准作为治疗 2 型糖尿病的口服药物。与格列本脲相比，格列美脲可刺激胰腺分泌胰岛素，并降低低血糖的风险。吡格列酮增加外周葡萄糖的摄取，同时减少肝脏的葡萄糖产生。两种药物相结合，可提高人体对胰岛素的敏感性，使血红蛋白 Alc 水平降低 1-2%。吡格列酮和格列美脲也对血脂和血压产生有利的影响。此外，吡格列酮已被证明可以降低某些心血管事件的风险，为大血管益处提供了证据。吡格列酮和格列美脲的副作用最小，体重增加和水肿会带来最大的不适和并发症。尽管风险很小，但必须监测患者是否发生心力衰竭。已制定指南，根据心脏危险因素限制患者选择使用吡格列酮。一般来说，吡格列酮和格列美脲的耐受性良好。 (c) 2007 年《Prous Science》。版权所有。
The combination of pioglitazone hydrochloride, a thiazolidinedione, and glimepiride, a sulfonylurea, has been approved in many countries worldwide as an oral agent for the management of type 2 diabetes. Glimepiricle stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. Pioglitazone increases glucose uptake in the periphery while decreasing glucose production by the liver. Combined, the two agents increase the body's sensitivity to insulin to reduce hemoglobin Alc levels by 1-2%. Pioglitazone and glimepiride also produce favorable effects on lipid profiles and blood pressure. Additionally, pioglitazone has proven to decrease the risk of certain cardiovascular events, providing evidence for macrovascular benefits.Side effects are minimal with pioglitazone and glimepiride, with weight gain and edema providing the most discomfort and complications. Patients must be monitored for the development of heart failure, though the risk is small. Guidelines are in place to limit patient selection for the use of pioglitazone based on cardiac risk factors. In general, pioglitazone and glimepiride are well tolerated. (c) 2007 Prous Science. All rights reserved.